全球临床肿瘤学下一代定序市场

预计到 2030 年全球临床肿瘤学下一代定序市场规模将达到 12 亿美元

全球临床肿瘤学新一代定序市场规模预计在2024年为4.899亿美元，预计到2030年将达到12亿美元，2024年至2030年的复合年增长率为15.8%。全基因组定序是本报告分析的细分市场之一，预计其复合年增长率为17.7%，到分析期结束时达到7.332亿美元。全EXOME定序细分市场在分析期间的复合年增长率估计为14.2%。

美国市场规模估计为 1.335 亿美元，中国市场预计复合年增长率为 21.3%

美国临床肿瘤学新一代定序市场规模预计在2024年达到1.335亿美元。作为世界第二大经济体，中国预计在2030年市场规模将达到2.62亿美元，在2024-2030年的分析期间内，复合年增长率为21.3%。其他值得关注的区域市场包括日本和加拿大，预计在分析期间内，这两个市场的复合年增长率分别为11.5%和14.3%。在欧洲，预计德国市场的复合年增长率约为12.6%。

全球临床肿瘤学下一代定序市场—主要趋势与驱动因素摘要

为什么次世代定序仪将改变临床肿瘤学的模式？

次世代定序(NGS) 技术透过在分子层面上对癌症进行更深入、更精准的理解，彻底改变了临床肿瘤学。与传统诊断方法不同，NGS 能够全面分析癌症基因组，识别基因突变、拷贝数变异、基因融合以及其他对肿瘤表征至关重要的生物标记。随着癌症治疗日益转向精准医疗，NGS 在指导个人化治疗、预测治疗反应以及监测疾病进展和復发方面发挥核心作用。 NGS 能够快速且经济高效地处理大量基因组数据，这显着加速了其在临床肿瘤学实践中的应用。肿瘤学家目前正在使用基于 NGS 的检测方案进行伴随诊断、标靶治疗选择、免疫治疗合格，甚至筛检遗传性癌症。这些分子层面的洞察正在改变癌症的诊断、分类和治疗方式，从而改善患者的预后并更有效地利用医疗资源。随着全球癌症发生率持续上升，NGS 正成为现代肿瘤学工作流程中的重要工具，在治疗的每个阶段都能实现精准决策。

技术进步和平台创新如何推动市场成长？

临床肿瘤NGS市场由快速的技术进步和定序平台、工作流程和数据解读工具的持续创新所驱动。从全基因组和全EXOME定序到标靶基因组合，高通量定序技术的不断发展，为多样化的临床需求提供了灵活且可扩展的解决方案。定序速度、准确性和价格的提升，使得NGS在从学术中心到社区肿瘤诊所等医疗机构中更加普及。先进的生物资讯学平台现已整合到临床流程中，能够根据AMP、ASCO和CAP等国际指南实现自动化变异调用、解读和报告。此外，基于液态切片的循环肿瘤DNA (ctDNA) NGS检测作为一种非侵入性、即时的癌症检测和监测工具，其发展势头强劲。小型化测序平台和云端基础的资料储存解决方案进一步简化了临床实施。这些技术进步不仅缩短了周转时间和成本，还将NGS的临床效用从晚期癌症扩展到早期检测、筛检和纵向监测。

临床实践趋势、法规结构和区域动态将在市场扩张中发挥什么作用？

NGS 在临床肿瘤学中的应用受到临床实践趋势、监管指南和区域特定医疗保健动态融合的影响。临床医生对基因突变对预后和治疗影响的认识不断提高，这推动了标准化基因组检测作为常规癌症诊断一部分的转变。 FDA、EMA 和 PMDA 等监管机构正在加快基于 NGS 的伴随诊断的核准，以促进其融入临床实践。同时，支付方对基因组检测的接受度以及不断演变的报销政策，正在推动主要市场的可负担性和采用率。在北美和西欧等已开发地区，先进的数位基础设施和先进的医疗保健生态系统正在支援临床 NGS 的广泛应用。同时，在亚太地区和拉丁美洲，政府主导的基因组学倡议、不断扩展的肿瘤治疗基础设施以及私人医疗保健机构不断增加的投资正在推动市场发展。诊断公司、製药公司和学术研究机构之间的合作也在推动创新和市场渗透。儘管存在数据解释复杂和技术纯熟劳工短缺等挑战，但全球向循证癌症医学的转变已使 NGS 牢牢占据了临床支柱的地位。

影响临床肿瘤学 NGS 市场的核心成长动力是什么？

临床肿瘤学下一代定序市场的成长受到多种因素的驱动，这些因素源自于技术进步、不断发展的临床需求和不断变化的医疗保健服务模式。全球癌症发生率的上升和向精准肿瘤学的转变极大地推动了对全面分子分析解决方案的需求。定序化学、多路復用和自动化方面的技术突破使 NGS 更快、更可靠、更具成本效益。液态切片和单细胞测序等新型测试形式的出现，正在将 NGS 的应用领域从诊断扩展到即时监控和微小残留疾病检测。 NGS 在治疗指导中的应用日益增多，尤其是在免疫肿瘤学和标靶治疗中，这增强了其临床相关性。伴随诊断的日益普及和肿瘤特异性NGS 面板的监管核准，正在加速其在治疗中心的应用。 NGS 越来越多地融入电子健康记录和数位病理工作流程，正在增强临床决策支援。此外，公共和私人基因组资料库的广泛普及，以及合作研究生态系统的完善，正在丰富NGS资料的解读。患者认知的提升、个人化医疗的需求以及医疗机构对分子诊断领域投资的不断增加，进一步推动了全球临床肿瘤NGS市场的扩张。

部分

技术类型（全基因组定序、全EXOME定序、标靶定序、重定序）、工作流程（NGS 前定序、NGS 定序、NGS 资料分析）、应用（筛检应用、伴随诊断应用、其他诊断应用）、最终用途（医院最终用途、诊所最终用途、实验室最终用途）

受访公司范例

• Agilent Technologies, Inc.
• Becton, Dickinson and Company（BD）
• Beijing Genomics Institute（BGI）
• bioMerieux SA
• Bio-Rad Laboratories, Inc.
• Caris Life Sciences
• Eurofins Scientific SE
• F. Hoffmann-La Roche Ltd.
• Foundation Medicine, Inc.
• Guardant Health, Inc.
• Illumina, Inc.
• Myriad Genetics, Inc.
• Oxford Nanopore Technologies Ltd.
• Pacific Biosciences of California, Inc.
• Partek Incorporated
• PerkinElmer, Inc.
• Qiagen NV
• Takara Bio Inc.
• Thermo Fisher Scientific Inc.
• Zymo Research Corporation

人工智慧集成

全球产业分析师正在利用可操作的专家内容和人工智慧工具改变市场和竞争情报。

Global Industry Analysts 并未遵循典型的 LLM 或特定产业的 SLM查询，而是建立了一个从全球专家收集的内容库，其中包括影片录影、部落格、搜寻引擎研究以及大量的公司、产品/服务和市场数据。

关税影响係数

全球产业分析师根据公司总部所在国家、製造地、进出口状况（成品和原始OEM）预测其竞争态势的变化。这种复杂且多面向的市场动态预计将以多种方式影响竞争对手，包括销货成本成本 (COGS) 上升、盈利下降、供应链重组以及其他微观和宏观市场动态。

目录

第一章调查方法

第二章执行摘要

• 市场概览
• 主要企业
• 市场趋势和驱动因素
• 全球市场展望

第三章市场分析

• 美国
• 加拿大
• 日本
• 中国
• 欧洲
• 法国
• 德国
• 义大利
• 英国
• 西班牙
• 俄罗斯
• 其他欧洲国家
• 亚太地区
• 澳洲
• 印度
• 韩国
• 其他亚太地区
• 拉丁美洲
• 阿根廷
• 巴西
• 墨西哥
• 其他拉丁美洲
• 中东
• 伊朗
• 以色列
• 沙乌地阿拉伯
• 阿拉伯聯合大公国
• 其他中东地区
• 非洲

第四章 竞赛

Global Clinical Oncology Next Generation Sequencing Market to Reach US$1.2 Billion by 2030

The global market for Clinical Oncology Next Generation Sequencing estimated at US$489.9 Million in the year 2024, is expected to reach US$1.2 Billion by 2030, growing at a CAGR of 15.8% over the analysis period 2024-2030. Whole Genome Sequencing, one of the segments analyzed in the report, is expected to record a 17.7% CAGR and reach US$733.2 Million by the end of the analysis period. Growth in the Whole Exome Sequencing segment is estimated at 14.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$133.5 Million While China is Forecast to Grow at 21.3% CAGR

The Clinical Oncology Next Generation Sequencing market in the U.S. is estimated at US$133.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$262.0 Million by the year 2030 trailing a CAGR of 21.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 11.5% and 14.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.6% CAGR.

Global Clinical Oncology Next Generation Sequencing Market - Key Trends & Drivers Summarized

Why Is Next Generation Sequencing Transforming the Clinical Oncology Landscape?

Next Generation Sequencing (NGS) has revolutionized clinical oncology by enabling a deeper, more precise understanding of cancer at the molecular level. Unlike traditional diagnostic methods, NGS allows for the comprehensive profiling of cancer genomes, identifying genetic mutations, copy number variations, gene fusions, and other biomarkers critical to tumor characterization. As cancer treatment increasingly shifts toward precision medicine, NGS plays a central role in guiding personalized therapies, predicting treatment response, and monitoring disease progression or recurrence. The ability of NGS to process large volumes of genomic data rapidly and cost-effectively has significantly accelerated its adoption in clinical oncology practices. Oncologists are now using NGS-based panels for companion diagnostics, targeted therapy selection, immunotherapy eligibility, and even hereditary cancer screening. This molecular insight is transforming how cancers are diagnosed, classified, and treated, leading to better patient outcomes and more efficient use of healthcare resources. As cancer incidence continues to rise globally, NGS is becoming an indispensable tool in modern oncology workflows, enabling precision-driven decision-making at every stage of care.

How Are Technological Advancements and Platform Innovations Fueling Market Growth?

The clinical oncology NGS market is being propelled by rapid technological advancements and continuous innovation in sequencing platforms, workflows, and data interpretation tools. The evolution of high-throughput sequencing technologies-ranging from whole-genome and whole-exome sequencing to targeted gene panels-is offering flexible and scalable solutions tailored to diverse clinical needs. Improvements in sequencing speed, accuracy, and affordability are making NGS more accessible across healthcare settings, from academic centers to community oncology clinics. Advanced bioinformatics platforms are now integrated into clinical pipelines, enabling automated variant calling, interpretation, and reporting in compliance with international guidelines such as those by the AMP, ASCO, and CAP. Moreover, the development of liquid biopsy-based NGS tests-using circulating tumor DNA (ctDNA)-is gaining momentum as a non-invasive, real-time tool for cancer detection and monitoring. Miniaturized sequencing platforms and cloud-based data storage solutions are further simplifying clinical implementation. These technological strides are not only reducing turnaround times and lowering costs but also expanding the clinical utility of NGS beyond advanced-stage cancers into early detection, screening, and longitudinal monitoring.

What Role Do Clinical Practice Trends, Regulatory Frameworks, and Regional Dynamics Play in Market Expansion?

The adoption of NGS in clinical oncology is shaped by a convergence of clinical practice trends, regulatory guidelines, and region-specific healthcare dynamics. There is a growing shift toward standardized genomic testing as part of routine oncology diagnostics, driven by increasing awareness among clinicians about the prognostic and therapeutic implications of genetic mutations. Regulatory authorities such as the FDA, EMA, and PMDA are accelerating approvals for NGS-based companion diagnostics, facilitating integration into clinical practice. Simultaneously, payer acceptance and evolving reimbursement policies for genomic tests are enhancing affordability and adoption across key markets. In developed regions like North America and Western Europe, high digital infrastructure and advanced healthcare ecosystems support widespread use of clinical NGS, while in Asia-Pacific and Latin America, market growth is being fueled by government-led genomics initiatives, expanding oncology care infrastructure, and increasing investments by private healthcare providers. Collaborations between diagnostics companies, pharmaceutical firms, and academic research institutions are also driving innovation and market penetration. Despite challenges such as data interpretation complexity and skilled workforce shortages, the global shift toward evidence-based oncology care is firmly positioning NGS as a clinical mainstay.

What Are the Core Growth Drivers Shaping the Clinical Oncology NGS Market?

The growth in the clinical oncology next generation sequencing market is driven by several factors rooted in technological advancement, evolving clinical needs, and changing healthcare delivery models. The rising global cancer burden and the shift toward precision oncology are significantly increasing the demand for comprehensive molecular profiling solutions. Technological breakthroughs in sequencing chemistry, multiplexing, and automation are making NGS faster, more reliable, and increasingly cost-effective. The emergence of novel testing formats-such as liquid biopsies and single-cell sequencing-is expanding NGS application areas beyond diagnostics into real-time monitoring and minimal residual disease detection. Expanding use of NGS for therapy guidance, particularly in immuno-oncology and targeted treatments, is boosting its clinical relevance. Growing availability of companion diagnostics and regulatory approvals for tumor-specific NGS panels are accelerating adoption across treatment centers. The increasing integration of NGS into electronic medical records and digital pathology workflows is enhancing clinical decision support. Moreover, the proliferation of public and private genomic databases, along with collaborative research ecosystems, is enriching the interpretation of NGS data. Patient awareness, demand for personalized care, and growing healthcare investments in molecular diagnostics are further propelling the global expansion of the clinical oncology NGS market.

SCOPE OF STUDY:

The report analyzes the Clinical Oncology Next Generation Sequencing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Technology Type (Whole Genome Sequencing, Whole Exome Sequencing, Targeted Sequencing and Resequencing); Workflow (NGS Pre-Sequencing, NGS Sequencing, NGS Data Analysis); Application (Screening Application, Companion Diagnostics Application, Other Diagnostics Application); End-Use (Hospitals End-Use, Clinics End-Use, Laboratories End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 33 Featured) -

• Agilent Technologies, Inc.
• Becton, Dickinson and Company (BD)
• Beijing Genomics Institute (BGI)
• bioMerieux S.A.
• Bio-Rad Laboratories, Inc.
• Caris Life Sciences
• Eurofins Scientific S.E.
• F. Hoffmann-La Roche Ltd.
• Foundation Medicine, Inc.
• Guardant Health, Inc.
• Illumina, Inc.
• Myriad Genetics, Inc.
• Oxford Nanopore Technologies Ltd.
• Pacific Biosciences of California, Inc.
• Partek Incorporated
• PerkinElmer, Inc.
• Qiagen N.V.
• Takara Bio Inc.
• Thermo Fisher Scientific Inc.
• Zymo Research Corporation

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • Clinical Oncology Next Generation Sequencing - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Cancer Incidence Worldwide Throws the Spotlight on Next Generation Sequencing as a Cornerstone in Precision Oncology
  • Shift Toward Personalized Cancer Therapy Spurs Demand for Comprehensive Genomic Profiling Using NGS Platforms
  • Expansion of Companion Diagnostics and Targeted Therapy Approaches Strengthens Business Case for Oncology-Focused NGS Testing
  • Rapid Technological Advancements in Sequencing Speed and Cost Efficiency Drive Widespread Clinical Adoption of NGS
  • Growing Use of Tumor Mutation Burden and Biomarker Discovery Expands Addressable Market Opportunity for Clinical NGS
  • Integration of NGS in Oncology Care Pathways Enhances Treatment Stratification and Prognostic Decision-Making
  • Regulatory Approvals and Reimbursement Policies Accelerate Market Penetration of NGS-Based Oncology Panels
  • Increasing Adoption of Liquid Biopsy-Based NGS Tests Throws the Spotlight on Non-Invasive Cancer Detection Solutions
  • Emerging Role of NGS in Minimal Residual Disease Monitoring and Recurrence Prediction Fuels Demand for High-Sensitivity Panels
  • Clinical Trials and Pharma Partnerships for Oncology Drug Development Propel Use of NGS in Biomarker-Driven Research
  • Rising Use of Comprehensive Genomic Panels Over Single-Gene Tests Drives Demand for Scalable and Modular NGS Platforms
  • Growth in Cancer Molecular Tumor Boards and Genomics-Guided Decision Support Systems Enhances Clinical Utility of NGS Data
  • OEM Focus on Turnkey NGS Workflows and Automated Bioinformatics Pipelines Boosts Adoption in Clinical Oncology Labs
  • Global Expansion of Cancer Genomics Programs and National Precision Medicine Initiatives Strengthens Market Growth Outlook
  • Long-Term Shift Toward Data-Driven Oncology and Personalized Medicine Sustains Demand for Advanced Clinical NGS Solutions
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Clinical Oncology Next Generation Sequencing Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Clinical Oncology Next Generation Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Whole Genome Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Whole Genome Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Whole Genome Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Whole Exome Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Whole Exome Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Whole Exome Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Targeted Sequencing & Resequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Targeted Sequencing & Resequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Targeted Sequencing & Resequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Laboratories End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for NGS Pre-Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for NGS Pre-Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for NGS Pre-Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for NGS Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for NGS Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for NGS Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for NGS Data Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for NGS Data Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for NGS Data Analysis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Screening Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Screening Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Screening Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Companion Diagnostics Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Companion Diagnostics Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Companion Diagnostics Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Other Diagnostics Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Other Diagnostics Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Other Diagnostics Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Clinical Oncology Next Generation Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 41: USA Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 43: USA 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Technology Type - Percentage Breakdown of Value Sales for Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing for the Years 2015, 2025 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 46: USA 15-Year Perspective for Clinical Oncology Next Generation Sequencing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 47: USA Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 48: USA Historic Review for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 49: USA 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Workflow - Percentage Breakdown of Value Sales for NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis for the Years 2015, 2025 & 2030
  • TABLE 50: USA Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 51: USA Historic Review for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 52: USA 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Application - Percentage Breakdown of Value Sales for Screening Application, Companion Diagnostics Application and Other Diagnostics Application for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 55: Canada 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Technology Type - Percentage Breakdown of Value Sales for Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing for the Years 2015, 2025 & 2030
  • TABLE 56: Canada Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Canada Historic Review for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 58: Canada 15-Year Perspective for Clinical Oncology Next Generation Sequencing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 59: Canada Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Canada Historic Review for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 61: Canada 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Workflow - Percentage Breakdown of Value Sales for NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis for the Years 2015, 2025 & 2030
  • TABLE 62: Canada Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Canada Historic Review for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 64: Canada 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Application - Percentage Breakdown of Value Sales for Screening Application, Companion Diagnostics Application and Other Diagnostics Application for the Years 2015, 2025 & 2030
• JAPAN
  • Clinical Oncology Next Generation Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 65: Japan Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Japan Historic Review for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 67: Japan 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Technology Type - Percentage Breakdown of Value Sales for Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing for the Years 2015, 2025 & 2030
  • TABLE 68: Japan Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Japan Historic Review for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 70: Japan 15-Year Perspective for Clinical Oncology Next Generation Sequencing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 71: Japan Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Japan Historic Review for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 73: Japan 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Workflow - Percentage Breakdown of Value Sales for NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis for the Years 2015, 2025 & 2030
  • TABLE 74: Japan Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Japan Historic Review for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 76: Japan 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Application - Percentage Breakdown of Value Sales for Screening Application, Companion Diagnostics Application and Other Diagnostics Application for the Years 2015, 2025 & 2030
• CHINA
  • Clinical Oncology Next Generation Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 77: China Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: China Historic Review for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 79: China 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Technology Type - Percentage Breakdown of Value Sales for Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing for the Years 2015, 2025 & 2030
  • TABLE 80: China Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: China Historic Review for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 82: China 15-Year Perspective for Clinical Oncology Next Generation Sequencing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 83: China Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 84: China Historic Review for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 85: China 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Workflow - Percentage Breakdown of Value Sales for NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis for the Years 2015, 2025 & 2030
  • TABLE 86: China Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: China Historic Review for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 88: China 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Application - Percentage Breakdown of Value Sales for Screening Application, Companion Diagnostics Application and Other Diagnostics Application for the Years 2015, 2025 & 2030
• EUROPE
  • Clinical Oncology Next Generation Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 89: Europe Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 90: Europe Historic Review for Clinical Oncology Next Generation Sequencing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 91: Europe 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 92: Europe Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Europe Historic Review for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 94: Europe 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Technology Type - Percentage Breakdown of Value Sales for Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing for the Years 2015, 2025 & 2030
  • TABLE 95: Europe Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Europe Historic Review for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 97: Europe 15-Year Perspective for Clinical Oncology Next Generation Sequencing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 98: Europe Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Europe Historic Review for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 100: Europe 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Workflow - Percentage Breakdown of Value Sales for NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis for the Years 2015, 2025 & 2030
  • TABLE 101: Europe Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Europe Historic Review for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 103: Europe 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Application - Percentage Breakdown of Value Sales for Screening Application, Companion Diagnostics Application and Other Diagnostics Application for the Years 2015, 2025 & 2030
• FRANCE
  • Clinical Oncology Next Generation Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 104: France Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 105: France Historic Review for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 106: France 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Technology Type - Percentage Breakdown of Value Sales for Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing for the Years 2015, 2025 & 2030
  • TABLE 107: France Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 108: France Historic Review for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 109: France 15-Year Perspective for Clinical Oncology Next Generation Sequencing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 110: France Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 111: France Historic Review for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 112: France 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Workflow - Percentage Breakdown of Value Sales for NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis for the Years 2015, 2025 & 2030
  • TABLE 113: France Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 114: France Historic Review for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 115: France 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Application - Percentage Breakdown of Value Sales for Screening Application, Companion Diagnostics Application and Other Diagnostics Application for the Years 2015, 2025 & 2030
• GERMANY
  • Clinical Oncology Next Generation Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 116: Germany Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Germany Historic Review for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 118: Germany 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Technology Type - Percentage Breakdown of Value Sales for Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing for the Years 2015, 2025 & 2030
  • TABLE 119: Germany Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Germany Historic Review for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 121: Germany 15-Year Perspective for Clinical Oncology Next Generation Sequencing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 122: Germany Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Germany Historic Review for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 124: Germany 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Workflow - Percentage Breakdown of Value Sales for NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis for the Years 2015, 2025 & 2030
  • TABLE 125: Germany Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Germany Historic Review for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 127: Germany 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Application - Percentage Breakdown of Value Sales for Screening Application, Companion Diagnostics Application and Other Diagnostics Application for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 128: Italy Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Italy Historic Review for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 130: Italy 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Technology Type - Percentage Breakdown of Value Sales for Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing for the Years 2015, 2025 & 2030
  • TABLE 131: Italy Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Italy Historic Review for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 133: Italy 15-Year Perspective for Clinical Oncology Next Generation Sequencing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 134: Italy Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Italy Historic Review for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 136: Italy 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Workflow - Percentage Breakdown of Value Sales for NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis for the Years 2015, 2025 & 2030
  • TABLE 137: Italy Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Italy Historic Review for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 139: Italy 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Application - Percentage Breakdown of Value Sales for Screening Application, Companion Diagnostics Application and Other Diagnostics Application for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Clinical Oncology Next Generation Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 140: UK Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 141: UK Historic Review for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 142: UK 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Technology Type - Percentage Breakdown of Value Sales for Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing for the Years 2015, 2025 & 2030
  • TABLE 143: UK Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 144: UK Historic Review for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 145: UK 15-Year Perspective for Clinical Oncology Next Generation Sequencing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 146: UK Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 147: UK Historic Review for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 148: UK 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Workflow - Percentage Breakdown of Value Sales for NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis for the Years 2015, 2025 & 2030
  • TABLE 149: UK Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 150: UK Historic Review for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 151: UK 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Application - Percentage Breakdown of Value Sales for Screening Application, Companion Diagnostics Application and Other Diagnostics Application for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 152: Spain Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Spain Historic Review for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 154: Spain 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Technology Type - Percentage Breakdown of Value Sales for Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing for the Years 2015, 2025 & 2030
  • TABLE 155: Spain Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Spain Historic Review for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 157: Spain 15-Year Perspective for Clinical Oncology Next Generation Sequencing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 158: Spain Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Spain Historic Review for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 160: Spain 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Workflow - Percentage Breakdown of Value Sales for NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis for the Years 2015, 2025 & 2030
  • TABLE 161: Spain Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Spain Historic Review for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 163: Spain 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Application - Percentage Breakdown of Value Sales for Screening Application, Companion Diagnostics Application and Other Diagnostics Application for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 164: Russia Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Russia Historic Review for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 166: Russia 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Technology Type - Percentage Breakdown of Value Sales for Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing for the Years 2015, 2025 & 2030
  • TABLE 167: Russia Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Russia Historic Review for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 169: Russia 15-Year Perspective for Clinical Oncology Next Generation Sequencing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 170: Russia Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Russia Historic Review for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 172: Russia 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Workflow - Percentage Breakdown of Value Sales for NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis for the Years 2015, 2025 & 2030
  • TABLE 173: Russia Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Russia Historic Review for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 175: Russia 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Application - Percentage Breakdown of Value Sales for Screening Application, Companion Diagnostics Application and Other Diagnostics Application for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 176: Rest of Europe Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Rest of Europe Historic Review for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 178: Rest of Europe 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Technology Type - Percentage Breakdown of Value Sales for Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing for the Years 2015, 2025 & 2030
  • TABLE 179: Rest of Europe Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Rest of Europe Historic Review for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 181: Rest of Europe 15-Year Perspective for Clinical Oncology Next Generation Sequencing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 182: Rest of Europe Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Rest of Europe Historic Review for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 184: Rest of Europe 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Workflow - Percentage Breakdown of Value Sales for NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis for the Years 2015, 2025 & 2030
  • TABLE 185: Rest of Europe Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Rest of Europe Historic Review for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 187: Rest of Europe 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Application - Percentage Breakdown of Value Sales for Screening Application, Companion Diagnostics Application and Other Diagnostics Application for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Clinical Oncology Next Generation Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 188: Asia-Pacific Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 189: Asia-Pacific Historic Review for Clinical Oncology Next Generation Sequencing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 190: Asia-Pacific 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 191: Asia-Pacific Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Asia-Pacific Historic Review for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 193: Asia-Pacific 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Technology Type - Percentage Breakdown of Value Sales for Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing for the Years 2015, 2025 & 2030
  • TABLE 194: Asia-Pacific Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Asia-Pacific Historic Review for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 196: Asia-Pacific 15-Year Perspective for Clinical Oncology Next Generation Sequencing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 197: Asia-Pacific Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Asia-Pacific Historic Review for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 199: Asia-Pacific 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Workflow - Percentage Breakdown of Value Sales for NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis for the Years 2015, 2025 & 2030
  • TABLE 200: Asia-Pacific Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Asia-Pacific Historic Review for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 202: Asia-Pacific 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Application - Percentage Breakdown of Value Sales for Screening Application, Companion Diagnostics Application and Other Diagnostics Application for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Clinical Oncology Next Generation Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 203: Australia Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Australia Historic Review for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 205: Australia 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Technology Type - Percentage Breakdown of Value Sales for Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing for the Years 2015, 2025 & 2030
  • TABLE 206: Australia Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Australia Historic Review for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 208: Australia 15-Year Perspective for Clinical Oncology Next Generation Sequencing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 209: Australia Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Australia Historic Review for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 211: Australia 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Workflow - Percentage Breakdown of Value Sales for NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis for the Years 2015, 2025 & 2030
  • TABLE 212: Australia Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Australia Historic Review for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 214: Australia 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Application - Percentage Breakdown of Value Sales for Screening Application, Companion Diagnostics Application and Other Diagnostics Application for the Years 2015, 2025 & 2030
• INDIA
  • Clinical Oncology Next Generation Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 215: India Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 216: India Historic Review for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 217: India 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Technology Type - Percentage Breakdown of Value Sales for Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing for the Years 2015, 2025 & 2030
  • TABLE 218: India Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 219: India Historic Review for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 220: India 15-Year Perspective for Clinical Oncology Next Generation Sequencing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 221: India Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 222: India Historic Review for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 223: India 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Workflow - Percentage Breakdown of Value Sales for NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis for the Years 2015, 2025 & 2030
  • TABLE 224: India Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 225: India Historic Review for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 226: India 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Application - Percentage Breakdown of Value Sales for Screening Application, Companion Diagnostics Application and Other Diagnostics Application for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 227: South Korea Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 228: South Korea Historic Review for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 229: South Korea 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Technology Type - Percentage Breakdown of Value Sales for Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing for the Years 2015, 2025 & 2030
  • TABLE 230: South Korea Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 231: South Korea Historic Review for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 232: South Korea 15-Year Perspective for Clinical Oncology Next Generation Sequencing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 233: South Korea Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 234: South Korea Historic Review for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 235: South Korea 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Workflow - Percentage Breakdown of Value Sales for NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis for the Years 2015, 2025 & 2030
  • TABLE 236: South Korea Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 237: South Korea Historic Review for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 238: South Korea 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Application - Percentage Breakdown of Value Sales for Screening Application, Companion Diagnostics Application and Other Diagnostics Application for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 239: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Asia-Pacific Historic Review for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 241: Rest of Asia-Pacific 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Technology Type - Percentage Breakdown of Value Sales for Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing for the Years 2015, 2025 & 2030
  • TABLE 242: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Asia-Pacific Historic Review for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 244: Rest of Asia-Pacific 15-Year Perspective for Clinical Oncology Next Generation Sequencing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 245: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Rest of Asia-Pacific Historic Review for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 247: Rest of Asia-Pacific 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Workflow - Percentage Breakdown of Value Sales for NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis for the Years 2015, 2025 & 2030
  • TABLE 248: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Rest of Asia-Pacific Historic Review for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 250: Rest of Asia-Pacific 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Application - Percentage Breakdown of Value Sales for Screening Application, Companion Diagnostics Application and Other Diagnostics Application for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Clinical Oncology Next Generation Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 251: Latin America Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 252: Latin America Historic Review for Clinical Oncology Next Generation Sequencing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 253: Latin America 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 254: Latin America Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Latin America Historic Review for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 256: Latin America 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Technology Type - Percentage Breakdown of Value Sales for Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing for the Years 2015, 2025 & 2030
  • TABLE 257: Latin America Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Latin America Historic Review for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 259: Latin America 15-Year Perspective for Clinical Oncology Next Generation Sequencing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 260: Latin America Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Latin America Historic Review for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 262: Latin America 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Workflow - Percentage Breakdown of Value Sales for NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis for the Years 2015, 2025 & 2030
  • TABLE 263: Latin America Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Latin America Historic Review for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 265: Latin America 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Application - Percentage Breakdown of Value Sales for Screening Application, Companion Diagnostics Application and Other Diagnostics Application for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 266: Argentina Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Argentina Historic Review for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 268: Argentina 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Technology Type - Percentage Breakdown of Value Sales for Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing for the Years 2015, 2025 & 2030
  • TABLE 269: Argentina Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Argentina Historic Review for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 271: Argentina 15-Year Perspective for Clinical Oncology Next Generation Sequencing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 272: Argentina Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Argentina Historic Review for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 274: Argentina 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Workflow - Percentage Breakdown of Value Sales for NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis for the Years 2015, 2025 & 2030
  • TABLE 275: Argentina Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Argentina Historic Review for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 277: Argentina 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Application - Percentage Breakdown of Value Sales for Screening Application, Companion Diagnostics Application and Other Diagnostics Application for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 278: Brazil Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Brazil Historic Review for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 280: Brazil 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Technology Type - Percentage Breakdown of Value Sales for Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing for the Years 2015, 2025 & 2030
  • TABLE 281: Brazil Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Brazil Historic Review for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 283: Brazil 15-Year Perspective for Clinical Oncology Next Generation Sequencing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 284: Brazil Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Brazil Historic Review for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 286: Brazil 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Workflow - Percentage Breakdown of Value Sales for NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis for the Years 2015, 2025 & 2030
  • TABLE 287: Brazil Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Brazil Historic Review for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 289: Brazil 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Application - Percentage Breakdown of Value Sales for Screening Application, Companion Diagnostics Application and Other Diagnostics Application for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 290: Mexico Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Mexico Historic Review for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 292: Mexico 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Technology Type - Percentage Breakdown of Value Sales for Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing for the Years 2015, 2025 & 2030
  • TABLE 293: Mexico Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Mexico Historic Review for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 295: Mexico 15-Year Perspective for Clinical Oncology Next Generation Sequencing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 296: Mexico Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Mexico Historic Review for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 298: Mexico 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Workflow - Percentage Breakdown of Value Sales for NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis for the Years 2015, 2025 & 2030
  • TABLE 299: Mexico Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Mexico Historic Review for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 301: Mexico 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Application - Percentage Breakdown of Value Sales for Screening Application, Companion Diagnostics Application and Other Diagnostics Application for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 302: Rest of Latin America Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Rest of Latin America Historic Review for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 304: Rest of Latin America 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Technology Type - Percentage Breakdown of Value Sales for Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing for the Years 2015, 2025 & 2030
  • TABLE 305: Rest of Latin America Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Rest of Latin America Historic Review for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 307: Rest of Latin America 15-Year Perspective for Clinical Oncology Next Generation Sequencing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 308: Rest of Latin America Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Rest of Latin America Historic Review for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 310: Rest of Latin America 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Workflow - Percentage Breakdown of Value Sales for NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis for the Years 2015, 2025 & 2030
  • TABLE 311: Rest of Latin America Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Rest of Latin America Historic Review for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 313: Rest of Latin America 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Application - Percentage Breakdown of Value Sales for Screening Application, Companion Diagnostics Application and Other Diagnostics Application for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Clinical Oncology Next Generation Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 314: Middle East Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 315: Middle East Historic Review for Clinical Oncology Next Generation Sequencing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 316: Middle East 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 317: Middle East Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Middle East Historic Review for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 319: Middle East 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Technology Type - Percentage Breakdown of Value Sales for Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing for the Years 2015, 2025 & 2030
  • TABLE 320: Middle East Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Middle East Historic Review for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 322: Middle East 15-Year Perspective for Clinical Oncology Next Generation Sequencing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 323: Middle East Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 324: Middle East Historic Review for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 325: Middle East 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Workflow - Percentage Breakdown of Value Sales for NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis for the Years 2015, 2025 & 2030
  • TABLE 326: Middle East Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 327: Middle East Historic Review for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 328: Middle East 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Application - Percentage Breakdown of Value Sales for Screening Application, Companion Diagnostics Application and Other Diagnostics Application for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 329: Iran Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 330: Iran Historic Review for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 331: Iran 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Technology Type - Percentage Breakdown of Value Sales for Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing for the Years 2015, 2025 & 2030
  • TABLE 332: Iran Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 333: Iran Historic Review for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 334: Iran 15-Year Perspective for Clinical Oncology Next Generation Sequencing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 335: Iran Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 336: Iran Historic Review for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 337: Iran 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Workflow - Percentage Breakdown of Value Sales for NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis for the Years 2015, 2025 & 2030
  • TABLE 338: Iran Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 339: Iran Historic Review for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 340: Iran 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Application - Percentage Breakdown of Value Sales for Screening Application, Companion Diagnostics Application and Other Diagnostics Application for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 341: Israel Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 342: Israel Historic Review for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 343: Israel 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Technology Type - Percentage Breakdown of Value Sales for Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing for the Years 2015, 2025 & 2030
  • TABLE 344: Israel Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 345: Israel Historic Review for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 346: Israel 15-Year Perspective for Clinical Oncology Next Generation Sequencing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 347: Israel Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 348: Israel Historic Review for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 349: Israel 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Workflow - Percentage Breakdown of Value Sales for NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis for the Years 2015, 2025 & 2030
  • TABLE 350: Israel Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 351: Israel Historic Review for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 352: Israel 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Application - Percentage Breakdown of Value Sales for Screening Application, Companion Diagnostics Application and Other Diagnostics Application for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 353: Saudi Arabia Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 354: Saudi Arabia Historic Review for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 355: Saudi Arabia 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Technology Type - Percentage Breakdown of Value Sales for Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing for the Years 2015, 2025 & 2030
  • TABLE 356: Saudi Arabia Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 357: Saudi Arabia Historic Review for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 358: Saudi Arabia 15-Year Perspective for Clinical Oncology Next Generation Sequencing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 359: Saudi Arabia Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 360: Saudi Arabia Historic Review for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 361: Saudi Arabia 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Workflow - Percentage Breakdown of Value Sales for NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis for the Years 2015, 2025 & 2030
  • TABLE 362: Saudi Arabia Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 363: Saudi Arabia Historic Review for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 364: Saudi Arabia 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Application - Percentage Breakdown of Value Sales for Screening Application, Companion Diagnostics Application and Other Diagnostics Application for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 365: UAE Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 366: UAE Historic Review for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 367: UAE 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Technology Type - Percentage Breakdown of Value Sales for Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing for the Years 2015, 2025 & 2030
  • TABLE 368: UAE Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 369: UAE Historic Review for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 370: UAE 15-Year Perspective for Clinical Oncology Next Generation Sequencing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 371: UAE Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 372: UAE Historic Review for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 373: UAE 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Workflow - Percentage Breakdown of Value Sales for NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis for the Years 2015, 2025 & 2030
  • TABLE 374: UAE Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 375: UAE Historic Review for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 376: UAE 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Application - Percentage Breakdown of Value Sales for Screening Application, Companion Diagnostics Application and Other Diagnostics Application for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 377: Rest of Middle East Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 378: Rest of Middle East Historic Review for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 379: Rest of Middle East 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Technology Type - Percentage Breakdown of Value Sales for Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing for the Years 2015, 2025 & 2030
  • TABLE 380: Rest of Middle East Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 381: Rest of Middle East Historic Review for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 382: Rest of Middle East 15-Year Perspective for Clinical Oncology Next Generation Sequencing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 383: Rest of Middle East Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 384: Rest of Middle East Historic Review for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 385: Rest of Middle East 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Workflow - Percentage Breakdown of Value Sales for NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis for the Years 2015, 2025 & 2030
  • TABLE 386: Rest of Middle East Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 387: Rest of Middle East Historic Review for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 388: Rest of Middle East 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Application - Percentage Breakdown of Value Sales for Screening Application, Companion Diagnostics Application and Other Diagnostics Application for the Years 2015, 2025 & 2030
• AFRICA
  • Clinical Oncology Next Generation Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 389: Africa Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 390: Africa Historic Review for Clinical Oncology Next Generation Sequencing by Technology Type - Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 391: Africa 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Technology Type - Percentage Breakdown of Value Sales for Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing for the Years 2015, 2025 & 2030
  • TABLE 392: Africa Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 393: Africa Historic Review for Clinical Oncology Next Generation Sequencing by End-Use - Hospitals End-Use, Clinics End-Use and Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 394: Africa 15-Year Perspective for Clinical Oncology Next Generation Sequencing by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 395: Africa Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 396: Africa Historic Review for Clinical Oncology Next Generation Sequencing by Workflow - NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 397: Africa 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Workflow - Percentage Breakdown of Value Sales for NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis for the Years 2015, 2025 & 2030
  • TABLE 398: Africa Recent Past, Current & Future Analysis for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 399: Africa Historic Review for Clinical Oncology Next Generation Sequencing by Application - Screening Application, Companion Diagnostics Application and Other Diagnostics Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 400: Africa 15-Year Perspective for Clinical Oncology Next Generation Sequencing by Application - Percentage Breakdown of Value Sales for Screening Application, Companion Diagnostics Application and Other Diagnostics Application for the Years 2015, 2025 & 2030

IV. COMPETITION